Alkermes Plc (NASDAQ:ALKS) has earned a consensus rating of “Hold” from the fifteen analysts that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $64.09.
A number of analysts have commented on the company. Zacks Investment Research upgraded Alkermes from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research report on Monday. BidaskClub downgraded Alkermes from a “hold” rating to a “sell” rating in a research report on Saturday, January 20th. Barclays downgraded Alkermes from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $66.00 to $50.00 in a research report on Monday, October 16th. JPMorgan Chase & Co. set a $78.00 price objective on Alkermes and gave the stock a “buy” rating in a research report on Friday, October 27th. Finally, ValuEngine upgraded Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, December 1st.
In other Alkermes news, SVP James M. Frates sold 20,932 shares of Alkermes stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $47.58, for a total value of $995,944.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Laurie Keating sold 6,249 shares of Alkermes stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. The disclosure for this sale can be found here. Insiders have sold a total of 156,417 shares of company stock valued at $9,223,447 in the last 90 days. 5.34% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of ALKS. Toronto Dominion Bank raised its position in Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after purchasing an additional 212 shares during the last quarter. SG Americas Securities LLC bought a new position in Alkermes in the 4th quarter valued at $114,000. Quantbot Technologies LP bought a new position in Alkermes in the 3rd quarter valued at $126,000. Virtu Financial LLC bought a new position in Alkermes in the 3rd quarter valued at $201,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Alkermes in the 3rd quarter valued at $214,000. Hedge funds and other institutional investors own 99.31% of the company’s stock.
Shares of Alkermes (ALKS) traded down $1.43 during mid-day trading on Friday, hitting $54.26. The company’s stock had a trading volume of 589,710 shares, compared to its average volume of 969,574. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72. Alkermes has a 52 week low of $46.42 and a 52 week high of $64.04. The company has a market cap of $8,330.00, a P/E ratio of -48.85 and a beta of 1.94.
ILLEGAL ACTIVITY WARNING: “Alkermes Plc (ALKS) Receives $63.40 Average Target Price from Analysts” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/06/alkermes-plc-alks-receives-63-40-average-target-price-from-analysts.html.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.